Download PDF

1. Company Snapshot

1.a. Company Description

Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.


In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application.Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Show Full description

1.b. Last Insights on QLI

Qilian International Holding Group Limited's recent stock performance was driven by the company's successful listing on the Nasdaq Capital Market under the ticker symbol "BGM", effective August 11, 2024. This milestone marks a significant step in the company's growth strategy, providing increased visibility and accessibility to investors. Additionally, the company's announcement of trading under a new ticker symbol may have sparked renewed interest in the stock, contributing to its recent performance.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

Aug -13

Source: prnewswire.com

Card image cap

Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

Jul -12

Source: prnewswire.com

Card image cap

Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

Jun -18

Source: prnewswire.com

Card image cap

Qilian International plans to adjust industrial investment

May -17

Source: prnewswire.com

Card image cap

Qilian International Holding Group Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule

Jan -12

Source: prnewswire.com

Card image cap

Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jul -17

Source: None

Card image cap

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021

Sep -16

Source: GlobeNewsWire

Card image cap

Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone

Aug -05

Source: GlobeNewsWire

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.76%)

6. Segments

Oxytetracycline and Licorice Products and Traditional Chinese Medicine Derivatives

Expected Growth: 8.1%

Growing demand for natural health solutions and increasing adoption of traditional Chinese medicine drive the market growth, fueled by consumers seeking alternative remedies and preventive healthcare measures.

Heparin Products and Sausage Casing

Expected Growth: 7.4%

Growing demand for anticoagulants in medical procedures and increasing consumption of processed meat products drive the growth of heparin products and sausage casings. Expanding healthcare infrastructure and rising meat processing industries in Asia Pacific region further boost the market.

Fertilizer

Expected Growth: 5.5%

Increasing demand for organic and inorganic fertilizers, driven by growing awareness of sustainable agriculture practices and rising food security concerns, will fuel the segment's growth.

7. Detailed Products

Cement

Qilian International Holding Group Limited produces and sells cement, a binding agent used in construction, road construction, and other infrastructure projects.

Ready-Mix Concrete

The company offers ready-mix concrete, a mixture of cement, water, and aggregate, used in construction projects.

Aggregate

Qilian International Holding Group Limited extracts and sells aggregate, a material used in construction, including sand, gravel, and crushed stone.

Concrete Blocks

The company manufactures and sells concrete blocks, used in construction projects, including building walls, foundations, and other structures.

Cement-Based Products

Qilian International Holding Group Limited offers a range of cement-based products, including mortar, plaster, and tile adhesive.

8. Qilian International Holding Group Limited's Porter Forces

Forces Ranking

Threat Of Substitutes

Qilian International Holding Group Limited operates in a competitive industry, but the threat of substitutes is moderate due to the company's diversified product offerings and strong brand recognition.

Bargaining Power Of Customers

Qilian International Holding Group Limited's customers have a high bargaining power due to the availability of alternative products and services in the market.

Bargaining Power Of Suppliers

Qilian International Holding Group Limited has a diversified supplier base, which reduces the bargaining power of individual suppliers.

Threat Of New Entrants

The threat of new entrants in Qilian International Holding Group Limited's industry is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry in Qilian International Holding Group Limited's industry is high due to the presence of several established players and the need for continuous innovation to stay competitive.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.33%
Debt Cost 3.95%
Equity Weight 98.67%
Equity Cost 11.06%
WACC 10.96%
Leverage 1.35%

11. Quality Control: Qilian International Holding Group Limited passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fagron

A-Score: 5.6/10

Value: 4.5

Growth: 5.0

Quality: 6.1

Yield: 1.9

Momentum: 6.5

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
HUTCHMED

A-Score: 5.5/10

Value: 6.7

Growth: 7.4

Quality: 7.1

Yield: 0.0

Momentum: 4.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Esperion Therapeutics

A-Score: 5.2/10

Value: 9.0

Growth: 5.9

Quality: 6.1

Yield: 0.0

Momentum: 9.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
ANI Pharmaceuticals

A-Score: 5.0/10

Value: 4.3

Growth: 6.0

Quality: 4.4

Yield: 0.0

Momentum: 9.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Qilian International Holding

A-Score: 3.3/10

Value: 7.5

Growth: 3.0

Quality: 3.4

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
China SXT Pharmaceuticals

A-Score: 3.0/10

Value: 8.0

Growth: 3.3

Quality: 3.8

Yield: 0.0

Momentum: 1.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.41$

Current Price

5.41$

Potential

-0.00%

Expected Cash-Flows